-
Our Vision
to relieve patient suffering and enhance lives
Using our novel R&D platform for the advancement of life-changing medicines, we focus on developing and commercializing treatments for neurological and endocrine related disorders.
Learn More -
Tardive Dyskinesia
is an involuntary movement disorder
We have developed the first FDA-approved treatment for adults with tardive dyskinesia, an involuntary movement disorder associated with prolonged use of dopamine receptor blocking agents.
Learn More -
Endometriosis and Uterine Fibroids
Not all patients suffer the same way
In our collaboration with AbbVie for women’s health, we have a novel, oral treatment approved in the United States for the management of moderate to severe endometriosis pain and another therapy to manage heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Under the collaboration, a treatment is also being investigated for the management of polycystic ovary syndrome.
Learn More -
PARKINSON’S DISEASE
Is a chronic and progressive neurodegenerative disease
We have the first U.S. FDA-approved once-daily add-on therapy for patients with Parkinson’s disease experiencing "off" episodes. In collaboration with Voyager Therapeutics, we are also developing an innovative gene therapy for the treatment of Parkinson’s disease.
Learn More -
Congenital Adrenal Hyperplasia
is a genetic disorder that requires lifelong care
We are investigating a novel treatment for the management of classic congenital adrenal hyperplasia, a rare disorder that causes serious acute and long-term clinical problems beginning at birth.
Learn More
You are now leaving the Neurocrine website.
Neurocrine is not responsible for the content of linked third party websites. Please be aware that the privacy policies and terms of use on these sites are different from Neurocrine policies.